DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα
Clinical and Molecular Hepatology · 01.07.2026 · 32 (3) · 1201-1224
DOI: 10.3350/cmh.2025.1099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2026. Verfasst von Hyun Ahm Sohn und 25 weiteren Autor:innen. Beteiligte Einrichtung: Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea. Hauptthemen laut MEDLINE: PPAR alpha, DNA (Cytosine-5-)-Methyltransferase 1, Hepatocyte Nuclear Factor 4, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, National Research Council of Science and Technology, Aging Convergence Research Center.
Abstract (Originalsprache)
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Aberrant DNA methylation, which is primarily maintained by DNA methyltransferase 1 (DNMT1), has been linked to metabolic dysregulation; however, its contribution to MASLD pathogenesis remains poorly defined. This study aimed to elucidate the role of DNMT1-mediated methylation in transcriptional regulation during MASLD progression and to determine whether DNMT1 inhibition can reverse disease-associated epigenetic and transcriptional alterations.
Methods
We conducted integrated analyses of the liver transcriptome (n=131) and DNA methylome (n=106) of patients with biopsy-proven MASLD. We evaluated the effect of DNMT1 inhibition with 5-aza-4′-thio-2′-deoxycytidine (Aza-TdC) on a diet-induced MASLD mouse model. Multiomics approaches, including DNA methylome profiling, lipidomics, RNA sequencing, and chromatin immunoprecipitation sequencing, were applied to elucidate the role of DNMT1-mediated DNA methylation in regulating pathogenic gene expression.
Results
DNA methylome profiling revealed increased methylation variability associated with increased DNMT1 expression in MASLD patients. DNMT1 inhibition ameliorated dysregulated lipid metabolism by reducing hepatic triacylglycerol accumulation and inflammation. Aza-TdC treatment partially reversed MASLD-related hypermethylation of hepatocyte nuclear factor 4 alpha (HNF4α)- and peroxisome proliferator-activated receptor alpha (PPARα)-regulated genes, restoring their transcriptional activity. Notably, Aza-TdC reactivated the gluconeogenic enzyme-encoding gene phosphoenolpyruvate carboxykinase 1 (PCK1), which was hypermethylated and transcriptionally repressed in MASLD. Targeted DNA methylation of the PCK1 promoter using CRISPRoff confirmed the direct epigenetic regulation of PCK1 expression.
Conclusions
Targeting DNMT1 may mitigate lipid dysregulation and inflammation by reversing hypermethylation and restoring HNF4α- and PPARα-dependent gene transcription, highlighting DNMT1 as a potential therapeutic target for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea.
- Department of Functional Genomics, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Daejeon, Korea.
- Metabolic Regulation Research Center, KRIBB, Daejeon, Korea.
- Korea Bioinformation Center (KOBIC), KRIBB, Daejeon, Korea.
- Smart Farm Research Center, Korea Institute of Science and Technology (KIST), Gangneung Institute of Natural Products, Gangneung, Korea.
- Integrated Metabolomics Research Group, Metropolitan Seoul Center, Korea Basic Science Institute, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- National Research Council of Science and Technology
- Aging Convergence Research Center
- Korea Basic Science Institute
- Korea Research Institute of Bioscience and Biotechnology
- Research Initiative Program
Zitieren
APA
Sohn, H. A., Go, H., An, T. H., Lee, J. M., Kim, H. J., Haam, K., Magdy, A., Jung, H. J., Shin, Y. J., Lim, H. J., Jeong, Y., Bae, Y., Jung, Y., Park, S. H., Park, K. C., Song, M. J., Cho, E. W., Kwon, E. S., Park, J. H., …, & Innovative Target Exploration of NAFLD (ITEN) Consortium (2026). DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα. Clinical and Molecular Hepatology, 32(3), 1201-1224. https://doi.org/10.3350/cmh.2025.1099
Vancouver
Sohn HA, Go H, An TH, Lee JM, Kim HJ, Haam K, et al. DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα. Clinical and Molecular Hepatology. 2026;32(3):1201-1224. doi:10.3350/cmh.2025.1099
BibTeX
@article{Sohn2026,
author = {Sohn, Hyun Ahm and Go, Hanyong and An, Tae Hyeon and Lee, Jun Min and Kim, Hee-Jin and Haam, Keeok and Magdy, Amal and Jung, Hyo-Jung and Shin, Yang-Ji and Lim, Hyun Jung and Jeong, Yujin and Bae, Yejin and Jung, Youngae and Park, Seong-Hwan and Park, Kyung Chan and Song, Myeong Jun and Cho, Eun-Wie and Kwon, Eun-Soo and Park, Jeong Hwan and Choi, Murim and Hwang, Geum-Sook and Lee, Dong Hyeon and Oh, Kyoung-Jin and Kim, Won and Kim, Mirang and Innovative Target Exploration of NAFLD (ITEN) Consortium, Innovative Target Exploration of NAFLD (ITEN) Consortium},
title = {DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {3},
pages = {1201--1224},
doi = {10.3350/cmh.2025.1099}
}
EUVIMED